LAFAYETTE, La. - A jury in the first federal Actos bladder cancer trial will be asked if manufacturer defendant Takeda Pharmaceutical Co. Ltd. acted in bad faith in failing to preserve or destroying relevant evidence, the trial judge decided in an opinion issued Jan. 27 as jury selection began (In Re: Actos $(Pioglitazone$) Products Liability Litigation, MDL Docket No. 2299, No. 6:11-md-2299, W.D. La.).